The mouse genome possesses five genes encoding proteins homologous to human Leu-13. The Leu-13 protein associates with immune cell receptor activation complexes: a monoclonal antibody against Leu-13 induces T and B cells to form homotypic aggregates, inhibits activation-induced proliferation and induces the shedding of L-selectin. The mouse fragilis proteins have not been previously analyzed as components of the immune response. Antibody and nucleic acid reagents were generated that are specific for each of the five fragilis gene products. Expression of some of these genes (fragilis and fragilis3) is wide spread in a variety of mouse immune (and nonimmune) tissues while others (fragilis5) appear to be much more restricted. These proteins have been predicted to span the membrane twice with both amino-and carboxyl-terminal sequences extracellular: we show that a highly conserved loop of the protein between the transmembrane domains is intracellular. The fragilis proteins are associated with tetraspanin proteins CD81 and CD9: B cell activation positions fragilis into lipid rafts along with the CD81, CD19, and CD21. The mouse functional equivalent to human Leu-13 may not be single gene product, but instead may require the contribution of multiple fragilis proteins.
Introduction
The mouse fragilis gene family consists of five functional genes on murine chromosome 7 and at least three pseudogenes distributed elsewhere in the genome. 1 The fragilis genes are highly homologous to a similar family of genes in the human (the Ifitm family) that possesses at least four members, including Ifitm1, which is also known as Leu-13 and 9-27. 2 The production of monoclonal antibodies against the Leu-13 protein has allowed extensive studies on the functions of the protein. 3, 4 Multiple members of this gene family have been found in other vertebrate species studied including four such genes in the rat, 2, 5, 6 at least two in the cow 6, 7 and one in the electric torpedo ray. 8 The Leu-13 protein has been functionally defined as contributing to cell-to-cell homotypic adhesions, 4, 9, 10 depressing proliferation, 4, [11] [12] [13] and modulating cell activation. The Leu-13 protein has been found complexed with the CD81 protein (also known as TAPA-1), a widely expressed tetraspanin protein. 11, 14 One well-characterized Leu-13 complex is that of CD21/CD19/CD81/ Leu-13 on the surface of B cells. 11, [15] [16] [17] Signaling though this complex is implicated in lowering the threshold of activation required for antigen-specific B cell activation.
Crosslinking the Leu-13 protein directly has been shown to downmodulate the expression of L-selectin on the surface of lymphocytes in a tyrosine kinase-dependent, protein kinase-C independent pathway. 18 The expression and function of the other members of this human gene family has not been extensively studied although the high degree of similarity to the Leu-13 protein suggests conserved function(s). Computer scanning of predicted molecular structures suggested similarity between the Leu-13 structure and that of a putative prion structure; 19 the significance of this similarity, if any, is not known.
The five mouse fragilis genes have primarily been analyzed as developmental markers during germ cell development. 1, [20] [21] [22] [23] Two independent groups identified various members of the fragilis gene family (also known as the mil-1, 2 or 3 genes) as being differentially expressed during the development of the primordial germ cells. Fragilis expression is induced in epiblast tissue by interaction with extraembryonic ectoderm. The expression of fragilis continues as the cells migrate within the blastocyst to continue their germ cell differentiation. Embryo transcript staining and transcript analysis identified specific cell types/structures that differentially expressed the fragilis, fragilis2 and fragilis3 genes; little to no expression of the fragilis4 or fragilis5 genes was observed. 1 The function of the fragilis proteins in germ cell development was not determined since the focus of these reports was in using the expression of the fragilis genes as markers of cell migration and differentiation.
The Leu-13/fragilis proteins may also be involved in the organization of more differentiated tissues. Dulbecco and co-workers 5,24-28 used differential display to isolate the rat8 gene product (homologous to the Leu-13 and fragilis genes), which demonstrated increased expression in cells important for the formation of domes within the maturing rat mammary gland. Antisense treatment of such cells to block production of the rat8 protein inhibited the ability of these cells to form dome structures. The rat8 protein was subsequently shown to be associated with lipid rafts (after DMSO treatment) and members of the Src family of tyrosine kinases; 28 neither the human nor mouse members of this family have been directly shown to localize to lipid rafts.
Our interest in the mouse fragilis gene family is twofold. First, the association of Leu-13 with CD81/CD21/ CD19 in human B cells suggests the same should be true in mouse B cells; modulation of mouse B cell signaling may be accomplished by modulation of the mouse fragilis proteins. However, it is not known which fragilis protein(s) is the murine functional homologue to human Leu-13. Second, we isolated fragilis5 as part of a differential display screen of normal and mutant mouse bone marrow. 29 The expression of fragilis5 had not been previously demonstrated and it was unclear what functional attributes this protein was providing for the mutant (microphthalmic) bone marrow. In this report, we describe the production of antibody and nucleic acid reagents to define the expression of the five fragilis gene products in immune tissues of the mouse. Using such epitope specific antibodies, we demonstrate the orientation of the protein within the membrane and we show coassociation of the various fragilis family proteins with members of the tetraspanin family. In addition, we verify localization of fragilis gene products within membrane signaling complexes.
Materials and methods

B220 and CD90 cell enrichment
All experiments involving the use of mice were carried out in accordance and permission of the University of Utah Institutional Animal Care and Use Committee. Spleens were removed from C57BL/6 mice, mechanically disrupted with a razor blade, and a single cell suspension was achieved by straining through a cell strainer. Red blood cells were lysed by suspension in ACK (0.1 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA) lysis solution for 5 min at room temperature. Cells were washed three times, strained and counted. Cells were incubated with CD45R (B220) microbeads or CD90 (Thy1.2) microbeads (Miltenyi Biotec, Auburn, CA, USA), according to Miltenyi protocols. Briefly, 1 Â 10 7 cells (90 ml) were incubated with beads (10 ml) for 15 min at 41C Cells were washed by addition of 2 ml of 0.5% BSA/PBS and then centrifuged. The cell pellet was resuspended in 500 ml buffer and loaded onto a prepared MACS MS separation column in the magnet. The column was washed with 3 Â 500 ml volumes, the column removed from the magnet, and cells eluted with one ml buffer. 
FACS analysis
RT-PCR
Mu-MLV reverse transcriptase was used to reverse transcribe RNA into cDNA. cDNA was amplified by PCR under the following conditions and with described primers. cDNA was denatured at 951C for 1 s, annealed at 551C for b-actin and fragilis and CD19, at 601C for CD3, fragilis3, 4, and 5, and at 631C for fragilis2 for 1 s and elongated at 721C for 7 s. PCR products were trace labeled with 32 P-labeled dCTP, resolved with sequencing gel electrophoresis under denaturing conditions and visualized by gel exposure to X-ray film overnight. Oligo sequences used are listed in Table 1 .
Cell lysis and stimulation
Cell lysates were prepared from mouse marrow or splenocytes, or the B cell 2PK3 or macrophage RAW cell lines were used from cell culture. Red blood cells were lysed in ACK lysis buffer and cells washed. Cells were then lysed in CHAPS (5 M NaCl, 0.1 M Na Phos, 0.5 M EDTA, NaF, 0.2 M Na Vanadate, 10 mM CHAPS and complete mini protease tablet (Roche, Indianapolis, IN, USA), RIPA or TNEV (10 mM Tris-Cl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM Na orthovanadate, and complete mini protease tablet) for 20 min on ice before centrifugation to remove nuclear material.
Bone marrow cells were obtained by flushing femurs with RPMI. Bone marrow macrophages were differentiated from bone marrow cells by treatment with L929 supernatant for 7 days. The final day of growth was in nutridoma media without L929 supernatant. Mucosal mast cells (MMC) were grown as described. 30 Bone marrow derived macrophages were obtained by culturing total bone marrow cells in M-CSF for 7 days, saving only the adherent cells.
Western blot analysis
Cell lysates were run on 16% or 4-20% gradient TrisGlycine precast gels (Invitrogen, Carlsbad, CA, USA). Protein was then transferred to Immobilon-P transfer membrane (Millipore, Billerica, MA, USA), in 25 mM Tris, 0.2 M glycine, 20% methanol buffer. Membranes were rinsed in methanol, air-dried, and blocked in 5% milk 20 mM Tris-HCl pH 7.5, 150 mM NaCl, and 0.1% Tween-20. Proteins were detected with proper antibody followed by a horseradish peroxidase conjugated secondary antibody. Signal was detected by addition of Supersignal West Pico Chemiluminescent substrate (Pierce, Rockford, IL, USA).
Immunoprecipitation
Lysates were precleared with protein G or protein A sepharose (Sigma, St Louis, MO, USA) then immunoprecipitated with antibody and protein G sepharose overnight at 41C The sepharose-antibody complex was washed five times and then resuspended in sample buffer (Tris-HCl/SDS, 20% glycerol, 4% SDS, 0.2 M DTT, and 0.0001% bromophenol blue).
Sucrose gradient lipid raft fractionation 1 Â 10 8 2PK3 cells were resuspended in 1 ml media on ice as described. 31 In total, 10 mg each of biotin a-IgM and biotin a-CD19 or biotin rat IgG2a and biotin IgA were added and incubated for 30 min on ice. Avidin (5 mg/ml) was added for an additional 30 min on ice. The cells were washed three times in ice cold PBS before lysis in 1 ml TNEV for 30 min on ice with 10 strokes of a dounce homogenizer. Lysates were spun for 10 min at 13 000 r.p.m. to clear. Supernatants were collected and 1 ml 85% sucrose TNEV was added and mixed. The lysate was placed in the bottom of a Beckman 14 Â 89 centrifuge tube and overlaid with 7 ml 35% sucrose TNEV and then 4 ml 5% sucrose TNEV before centrifugation at 41C at 200 000 g for 20 h in a Beckman ultracentrifuge. A measure of 1 ml fractions were collected from the top. Sample buffer was added to each fraction and samples were separated on 4-20 or 8-16% Tris-Glycine gels.
Results
Fragilis gene products are expressed in a wide variety of tissues and cells The mouse genome possesses five genes on chromosome 7 that belong to the fragilis family ( Figure 1a ). 1 The genes, known as fragilis and fragilis2-5, are within about 68 000 bp of each other on the chromosome; transcription is oriented 5 0 to 3 0 telomere to centromere except for fragilis2, which is inverted compared to the rest. The family also appears to possess pseudogenes on mouse chromosomes 8, 9, 16, and 17. The sequences of these genes are highly homologous, each possessing a predicted amino terminal extracellular region, a transmembrane region and a highly conserved putative cytoplasmic domain followed by another transmembrane-like domain. The sequence of these five genes between the two putative transmembrane domains is highly conserved; however, predicted sequences at the amino and carboxyl terminal are highly variable between the five family members. Sequence modeling suggests the conserved sequence between the two putative transmembrane sequences is intracellular, but that has not been demonstrated for any member of the family regardless of species. In order to analyze the relative expression of the five fragilis family members in various mouse tissues and cells, we generated oligonucleotide sequences specific for each of the fragilis transcripts. Each fragilis gene consists of only two exons; the oligonucleotides are designed to span the sole intron to ensure PCR analysis of mRNA (cDNA) not genomic DNA. Additionally, we generated a series of antisera for the fragilis proteins. For each fragilis protein we generated oligopeptides that were conjugated to an appropriate protein carrier and used to generate rabbit polyclonal antisera (Figure 1b) . Two different peptides were generated for the fragilis5 protein sequence (fragilis5 and 5-67). Finally, a consensus peptide (INT-68) was created (matching that of fragilis except for a substitution of an F for a Y residue) for the putative cytoplasmic domain; antisera specific for this peptide could potentially react with the various fragilis family members with the possible exception of fragilis4 whose sequence is most divergent.
A variety of cell lines and primary cells were analyzed for expression of the various fragilis genes using RT-PCR with the gene-specific oligonucleotide sequences. As shown in Figure 2a , the analysis of the mouse T cell line (EL-4), B cell (2PK3), fibroblast (L929) and macrophage (RAW) showed diverse expression of the five family members. Relative to the L929 and RAW cells, fragilis expression is low in the B and T cell lines. Fragilis2 expression is highest in the fibroblast line while fragilis3 is abundantly expressed in all four cell types. Fragilis4 shows low but ubiquitous expression and fragilis5 is primarily limited to the RAW macrophage. Thus, for each of these cell types, a diverse population of fragilis proteins is likely.
The expression of these family members has been defined as being responsive to interferon treatment. 2 Accordingly, in Figure 2b , transcripts are shown from total bone marrow (BM), bone marrow derived macrophages (BMMf) and bone marrow derived MMC treated with IFN-b. Similar to the preceding data, a wide variety of fragilis genes are transcriptionaly active in such cell types; however, responses to interferon treatment were muted. The data from these two panels indicate that although the structures of the fragilis family genes are very similar and the linkage on the chromosome tight, they still show diverse expression profiles in cells of the immune response.
These analyses were expanded using enriched splenic T and B cells (Figure 3 ). Fresh splenocytes were fractionated, using antibodies bound to magnetic beads, into populations of B cell enriched (B220 þ ) and B cell depleted (B220À) pools, and T cell enriched (CD90 þ ) and T cell depleted (CD90À) pools. FACS analysis of these enriched pools showed greater than 90% enrichment for the B220 and 80% enrichment for CD90 (data not shown). Gene specific transcripts were analyzed using RT-PCR. Fragilis expression was evident in both T and B cell enriched and depleted samples suggesting a ubiquitous expression in splenocytes. Fragilis3 was more highly expressed in splenocytes that were neither T cells nor B cells: the other major cell types in the spleen include macrophages (about 10%), neutrophils (about 2-5%) and mast cells/basophils (usually only a few per cent of total). Fragilis5 showed a similar expression profile to that of fragilis3; highest expression in non-T, B lineage cells. Fragilis2 shows a ubiquitous expression profile (similar to fragilis), as does fragilis4 although its expression appears to be somewhat enriched for the T and B cell pools.
The polyclonal antisera raised against the specific fragilis gene products were then used for immunoprecipitation analysis from lysates prepared from 35 S-labeled L929 and RAW cells (Figure 4) . Products for fragilis, fragilis3, and faintly fragilis4 and fragilis5 (the 5-67 antisera) were observed from the L929 extracts. The antibody generated to recognize the conserved presumed cytoplasmic loop sequence of the fragilis proteins (INT-68) identified a protein(s) of the appropriate molecular weight. Similar data were obtained from the RAW cell lysates. Again, fragilis and fragilis3 were the most abundant of the fragilis proteins made within the RAW cell, and fragilis2 protein was not detected.
Evidence of amino terminal proteolytic processing of fragilis protein
The entire coding sequence of fragilis5 was inserted into the vector pRSV. The T7 promoter was used in vitro to generate RNA that was then translated into protein using 35 S-labeled methionine and a rabbit reticulocyte extract. The labeled protein was then immunoprecipitated with the polyclonal antisera obtained from two animals injected with the 5-67 peptide (Figure 5a , lanes 5-66 and 5-67) and with the polyclonal antisera generated from two animals injected with the int-68 peptide (lanes INT-68 and INT-69). The two 5-67 antisera immunoprecipitated a single protein of the predicted size (about 13 000 mr); however, the INT-68 antisera identified a mix of products including the 13 000 mr protein and others of lesser size. These data suggest that the heterogeneous products identified with the INT-68 contained variable peptide sequences from the amino terminal end of the protein, and that the protein, once synthesized, was sensitive to protease digestion in vitro on the amino terminal end. Lysates prepared with nonsense RNA did not generate proteins reactive with these antisera (data not shown) and preimmune sera did not detect the in vitro transcribed and translated fragilis proteins (data not shown). These experiments were then expanded using 35 S-labeled methionine labeled, IFN-b treated L929 and RAW cells, immunoprecipitated with the INT-68 and 5-67 antisera (Figure 5b) . Even though the RAW cell clearly demonstrated fragilis5 transcripts, there is no evidence of fragilis5 protein in that cell (using the 5-67 antisera), while the L929 cell, which shows minimal fragilis5 transcription, does possess the fragilis5 protein.
Additionally, the RAW cell line (and to a lesser extent the L929 cell) shows a distinct set of smaller proteins recognized by the INT-68 antisera, similar to the profile in Figure 5a . These data suggest that either the fragilis5 protein is not stably expressed in the RAW cells (despite the presence of the transcript: see Figure 2a ) or that the epitope recognized by the 5-67 antisera (somewhere within the first 17 amino acids of the protein) is removed from the protein following synthesis in RAW cells. The fragilis5 protein, however, is detected in the fibroblast L929 cell line.
Defining the membrane orientation of the fragilis proteins The structure of the fragilis proteins suggests the protein spans the membrane with two transmembrane sequences with a highly conserved cytoplasmic loop in between (see Figure 1) . However, it has not been previously shown that this proposed orientation of the protein is correct and that the putative cytoplasmic loop S-met labeled RAW cells, and the L929 cell line (mock or treated with IFN-b, 100 U/ml for 18 h). Preimmune and immune sera specific for the peptides described above were used. The molecular weight of the product, 17 300 mr, is shown on right. The 5-67 antibody was generated to be specific for fragilis5 while the INT-68 antisera should recognize multiple members of the fragilis family.
Mouse fragilis gene products RA Smith et al is actually within the cell. The RAW macrophage cell line (which expresses fragilis, fragilis3, fragilis4 and fragilis5) was analyzed by FACS staining with the 5-67 and INT-68 antisera (Figure 6a ). Cells were fixed and were then either permeabilized or left intact. The preimmune antisera were used as negative controls. There was insignificant staining of the intact or permeabilized RAW cells with the 5-67 antisera presumably due to the processing of the protein described above. However, the INT-68 antisera showed strong reactivity to the permeabilized cells. Staining controls for the experiment were intracellular TNF-a (which showed staining only with the permeabilized cells) and extracellular F4-80 (which showed staining of both the intact and permeabilized cells).
A similar analysis was performed on splenic B and T cells (Figure 6b ) using the 5-67 and the INT-68 antisera. As shown previously (see Figure 3) , the B220 þ B cells and the CD90 þ T cells do not express fragilis5, thus we did not expect staining with the 5-67 antisera. However, the INT-68 antisera did bind to these cells after permeabilization. The FACS analysis data with the INT-68 antisera thus indicates the putative cytoplasmic loop sequence of these proteins (or at least that of fragilis) is protected from antibody binding in the intact cell, confirming its intracellular localization.
Colocalization of fragilis with tetraspanin proteins
The human Leu-13 protein has been described as part of a B cell complex including CD81, CD19, and CD21; however, it is not clear if Leu-13 can associate with all of these proteins, or if it shows preferential association with one or more members of the complex. We sought to examine the complex location of the fragilis proteins expressed by splenic cells by immunoprecipitating complexes with antisera against either CD81, CD19 or CD21, and determining with which protein(s) we could detect the various fragilis proteins. Resting splenocytes were lysed with CHAPs detergent to maintain complex formation, precipitated with either anti-CD81, anti-CD19 or anti-CD21, the precipitates resolved by SDS-PAGE, and analyzed by Western blot using the fragilis, fragilis3 and fragilis5 specific antisera. As shown in Figure 7a , the fragilis protein was found associated with CD81, but not with CD19 or CD21. Additionally, the fragilis3 protein could be slightly detected in the CD81 precipitation but not with CD19 or CD21. The fragilis5 protein was not evident in these assays. The fragilis 2 and 4 proteins were not detected in these immunoprecipitation experiments (data not shown).
B cell receptor coactivation with the CD21 complex moves both of these protein groups into lipid rafts to gain accessibility to the kinases that reside within the rafts. Thus, it was possible that we would find direct association of the fragilis proteins with the CD21 or CD19 proteins following cell activation. Accordingly, splenic cells were treated with antisera specific for the B cell receptor (anti-IgM), anti-CD21 antibodies, or both antibodies, or neither, to facilitate membrane re-organization (Figure 7b ). Complexes were then immunoprecipitated and analyzed by Western blot with antisera against fragilis, fragilis3 and fragilis5. The association of fragilis and fragilis3 proteins with CD81 did not change with the status of B cell activation: there was still no obvious association of the fragilis proteins with the CD19 protein.
These data suggest that moving the BCR and/or CD21 complexes into the lipid raft regions does not alter the association of the fragilis proteins with CD81, and does not enhance fragilis protein association with other components of that complex (CD19).
CD81 is one of 18 tetraspanin proteins that are found on the surface of lymphocytes. 32 Leu-13 was specifically linked to CD81 for the CD21-mediated coactivation of B cells; however, it is not known if other tetraspanin proteins can also form complexes with these family members. To evaluate this question, total bone marrow cells were lysed with CHAPS detergent and the lystates were immunoprecipitated with either anti-CD81 or anti-CD9, another member of the tetraspanin family that is found on bone marrow cells, and the presence of coassociated fragilis was detected by Western blot. As shown in Figure 7c , both CD9 and CD81 colocalize with the fragilis protein. These data suggest that the fragilis proteins may form associations with many of the tetraspanin family members.
To determine if fragilis localizes within lipid rafts following cellular activation, sucrose gradient centrifugation was utilized to separate dense membrane compartments from the less dense, cholesterol-bearing lipid rafts. The B cell line, 2PK3, was activated with anti-IgM and anti-CD19 (or mock activated with isotype controls), cells were lysed and analyzed. As shown in Figure 8 , Lyn is found in the raft fractions of activated and resting cells. However, CD21, CD81 and fragilis only move into the less dense, insoluble fraction after cellular activation. Thus, the fragilis proteins move with the CD21/CD19/ CD81 complex into lipid rafts following coligation activation of B cells.
Discussion
In this report we describe the functional expression of the fragilis gene products in tissues and cells of the mature mouse. Previous studies on fragilis expression and transcript localization were carried out by analyzing the development of primordial germ cells and have not included analyses of immune effector cells. These genes
immunoprecipitation: fragilis fragilis3 fragilis5 western: Figure 7 Differential localization of fragilis proteins following cellular activation. (a) Immunoprecipitation of resting splenocytes with antibodies against CD81, CD19 or CD21 (and isotype controls, C) under nondenaturing conditions followed by SDS-PAGE and Western blot analysis with rabbit polyclonal antibodies specific for fragilis, fragilis3 and fragilis5 (see Figure 1 ). (b) Splenocytes were activated with antibodies against surface IgM and CD21 (either together, alone, or with isotype controls). Cells were lysed under nondenaturing conditions (see Materials) and lysates were subjected to immunoprecipitation with antibodies against CD19 or CD81 (or isotype controls, C). Precipitates were resolved by SDS-PAGE and analyzed by Western blot using antisera specific for fragilis, fragilis3 and fragilis5. (c) Bone marrow cells were lysed under nondenaturing conditions, lysates were precipitated with antibodies against two different tetraspanin proteins, CD9 and CD81 (or isotype controls, C), and analyzed by Western blot using antisera specific for the fragilis protein.
are defined as belonging to a much larger family of interferon inducible genes; however, we do not see dramatic changes in their expression following treatment with type I interferon (IFN-b) . The expression of the five different fragilis family members is diverse with some cells and tissues showing considerable overlap, and others demonstrating much more limited expression. For example, fragilis5 expression is very limited while fragilis3 is expressed in most cells and tissues analyzed. Expression of the fragilis4 and fragilis5 genes was not detected during germ cell differentiation; the expression of these genes is evident in a variety of mature immune cell lineages.
One primary goal of this study was to determine the identification of the murine functional homologue to the Leu-13 protein. Leu 13 is produced by both human T and B cells. All of the fragilis family member transcripts except fragilis5 are expressed in T and B cell populations (Figures 2 and 3) . Fragilis and fragilis3 proteins show association with CD81 in splenocytes. These data suggest that both fragilis and fragilis3 could function as murine homologues to human Leu-13. The fragilis protein is clearly mobilized into lipid rafts following B cell coreceptor activation. This movement may be utterly dependent upon its coassociation with CD81 (which undergoes palmitoylation following co-receptor activation) or the fragilis protein itself may be similarly modified. Whether resting or activated, however, the fragilis proteins only show affinity to the tetraspanin component of such receptor complexes.
Results obtained in this report directly address the position of the fragilis proteins within the membrane of the cell. The presumed structure of the fragilis/Leu-13 family members has been inferred from the translated coding sequence as possessing two transmembrane-like domains with an internal conserved cytoplasmic loop (Figure 9a) . However, no test of this model has been previously reported. Antisera generated against this presumed cytoplasmic loop of the fragilis proteins does stain cells but only after permeabilization suggesting that this peptide sequence is within the cell. The amino terminal segment of the protein does not appear to possess a recognizable signal sequence yet it is plausible that it is extracellular with a transmembrane region between it and the cytoplasmic loop. However, it does seem likely that some processing of sequences on the Nterminus occurs depending upon the cell type analyzed.
More problematic for the position of the protein in the membrane is the location of the presumed second transmembrane domain. Fragilis2 protein truncates within this presumed second transmembrane domain while fragilis5 only possesses 3-4 amino acids that could be inferred as extracellular in location. Neither of these proteins would thus be expected to traverse the membrane using this second transmembrane domain since there would not be a significant positive charge on the carboxy terminus to hold it in place. Thus, it is more likely that this second presumed transmembrane region is simply membrane associated for some of the fragilis family members (Figure 9b ). Further experimentation using C-terminal antisera is required to determine the true membrane spanning structures of the various fragilis family members.
The fragilis and Leu 13 proteins have been shown to be associated with CD81. CD81 is a member of a large family of tetraspanin proteins. Interestingly, cells treated with some antibodies against the Leu-13 and the CD81 proteins have virtually the identical response (inducing homotypic aggregation and inhibiting activation-dependent proliferation), 4, 33 suggesting these two proteins either share signaling pathways independently, or that they make use of the same pathway as part of a complex. Our data showing fragilis association with CD9 raises the question of whether fragilis association with varied tetraspanins can alter the signaling potential of the cell. As antibodies against these various tetraspanin proteins become available, it will be of interest to determine their possible co-association with the fragilis family members. Figure 8 Fragilis proteins localize to lipid rafts after B cell activation. 2PK3 B cells were treated with control antibodies (mock) or with antibodies against surface IgM and CD19 as described in Materials. Cells were lysed and analyzed by discontinuous density sucrose sedimentation. In total, 12 equal fractions were collected and separated by SDS-PAGE (lightest fractions to the left) and analyzed by Western blot with antibodies against Lyn, the fragilis protein, CD21 and CD81. 
